We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
May 28, 2024
12:00 PM - 01:00 PM EDT
John H. Stone, MD, MPH
Emanuel Della Torre, MD, PhD
Yoh Zen, MD, PhD, FRCPath
Optimizing the Treatment Continuum With a Molecular-Based Approach in HER2+ GI Cancers
June 28, 2024
13:15 - 14:15 CEST
Josep Tabernero, MD, PhD
Sara Lonardi, MD
Zev A. Wainberg, MD
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Benjamin Levy, MD
Alexander Spira, MD, PhD, FACP
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
Jyoti Patel, MD
Pasi Antero Jänne, MD, PhD
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Helena Yu, MD
Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases
Charu Aggarwal, MD, MPH
Alexander Drilon, MD
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC
First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
Intracranial Activity of ROS1 TKIs
Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents
Next-Generation TKI Therapy for ROS1-Rearranged NSCLC
Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education